COVID-19: The risk of blood clots after coronavirus is eight times higher than after Oxford-AstraZeneca vaccine – Study | Science & Tech News
According to a study by the University of Oxford, the risk of developing a blood clot after COVID-19 is eight times higher than after administering the Oxford-AstraZeneca vaccine.
Cerebral vein thrombosis (CVT) occurred in 39 out of a million COVID-19 Patients compared with about five in a million people given the AstraZeneca Jab.
Live COVID updates from across the UK and around the world
In the study of over 500,000 Coronavirus In patients, the risk after infection was about 100 times higher than normal.
Many countries have restricted the use of the vaccine to certain age groups or have suspended its introduction – with Denmark reportedly even permanently removing the vaccine from its vaccination program very rare cases of blood clots.
The UK regulator has stated that the vaccine is still safe and effective, but has restricted its use in those under 30, as this age group is less likely to get serious coronavirus.
However, the Oxford study found that around a third (30%) of CVT reports following COVID-19 infection were in people under the age of 30.
Scientists said the technology used in Oxford-AstraZeneca’s vaccine, which uses an adenovirus, has been linked to a slightly increased risk of blood clots.
It’s the same explanation for that Johnson & Johnson vaccine, which was stopped in the US after a handful of coagulation reports there.
In over 480,000 people who have the Pfizer or Moderna Vaccines that use mRNA technology instead have CVT in about four in a million people.
The risk of developing CVT after taking one of these vaccines is about ten times lower than after being infected with coronavirus, the study said.
However, the researchers said comparisons should be interpreted with caution as data is still being collected.
Oxford University Professor Paul Harrison said, “We have drawn two important conclusions. First, COVID-19 significantly increases the risk of CVT and adds to the list of blood clotting problems that this infection causes.
“Second, the risk of COVID-19 is higher than current vaccines, even in those under the age of 30. This should be taken into account when considering the balance of risk and benefit for vaccination.”
And Professor Sir John Bell, the University’s Regius Professor of Medicine, told Sky News, “The best way if you want to have a bad clotting problem is to get COVID.
“And if you don’t get a vaccine you will get COVID, and if you do get COVID you are very, much more likely to have a bad clotting problem.
“As such, the vaccine’s clotting problems are pretty trivial compared to the actual risks of clotting problems in COVID.”
Analysis: Vaccination is safer than COVID for young people too
By Thomas Moore, science correspondent
There are many good reasons to avoid COVID, and this study puts blood clots firmly on the list.
It suggests that the risk of developing CVT – a blood clot in a vein that drains blood from the brain – is about 100 times higher than normal in the two weeks after being infected with COVID.
They also looked at a similar clot in a hepatic vein. Again, the risk after vaccination was much lower than with the disease.
The numbers in the study were too low to specifically examine the subgroup of people who have a brain clot combined with low blood platelets. This is the unusual feature that has led several countries to stop using the AstraZeneca vaccine in younger people.
However, the study highlights the benefits of vaccination.
Not only does this reduce the overall risk of blood clots compared to the disease, but also death and complications that affect the heart, lungs, kidney and brain. And of course not to forget the long COVID.
The older you are, the greater the benefits. But vaccination is also safer than disease for young people.
Countries disagree on the age of using an RNA vaccine instead of the AstraZeneca sting. It comes down to the interpretation of the evidence and this new study really doesn’t move that debate any further.